US EditionPublished • loading... • Updated
AbbVie to launch ovarian cancer drug in UK at US price
AbbVie will price its newly approved ovarian cancer drug in the UK equal to US levels while negotiating with NICE to secure fair valuation and access.
- AbbVie revealed plans to introduce its ovarian cancer treatment, ELAHERE, in the UK on September 29, 2025, pricing it the same as in the United States.
- This launch comes after ELAHERE received complete approval from the FDA in March 2024, secured European Commission clearance in November 2024, and obtained authorization from the UK MHRA in July 2025.
- ELAHERE is a first-in-class antibody-drug conjugate targeting folate receptor alpha, for adult patients with platinum-resistant high-grade serous ovarian cancer after one to three prior treatments.
- Jeff Stewart, AbbVie’s EVP and chief commercial officer, said developed markets must support innovative therapies to ensure sustainable access and worldwide patient benefits.
- AbbVie is in discussions with NICE to secure a fair value assessment, which will influence ELAHERE's availability and reflect AbbVie’s strategy to recognize innovation’s value.
Insights by Ground AI
11 Articles
11 Articles
AbbVie to Launch Ovarian Cancer Drug ELAHERE in UK at US Price Levels
New Delhi: AbbVie has announced that it will launch its ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) in the United Kingdom at a list price equivalent to that in the United States,...
·New Delhi, India
Read Full Article
PR Newswire+3 Reposted by 3 other sources
AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced plans to launch ELAHERE® (mirvetuximab soravtansine-gynx) in the U.K. at a list price equal to the U.S.,...
·United States
Read Full ArticleCoverage Details
Total News Sources11
Leaning Left1Leaning Right1Center7Last UpdatedBias Distribution78% Center
Bias Distribution
- 78% of the sources are Center
78% Center
11%
C 78%
11%
Factuality
To view factuality data please Upgrade to Premium
